Swiss Pharma Co. increases investment to increase output of gastro medicines

Ferring Pharmaceuticals plans to invest an additional Rs 500 crore in India . The Swiss company is looking to enter into distribution tie-ups with domestic companies to extend the reach of its life-saving drug Carbetocin .

Ferring Pharmaceuticals, a Swiss firm, plans to invest an additional Rs 500 crore in India's expansion of gastro-intestinal (GI) drugs over the next three years.Over the past five years, the organization has invested Rs 500 crore in an active pharmaceutical ingredient (API) laboratory and an R&D center in India.From its base in Ambernath, Maharashtra, the $2.6 billion company produces APIs for its leading GI drug Pentasa for the rest of the world.Ferring Pharmaceuticals president Per Falk said in an interview that the privately owned, specialty biopharmaceutical company is looking to enter into distribution tie-ups with domestic companies to extend the reach of its life-saving drug Carbetocin to avoid excessive bleeding after childbirth.

Ferring is supplying Carbetocin vials to India for a relatively affordable and sustainable price of Rs 25 per vial, according to Falk.On the private market, the therapy costs Rs 450-500 per dose.Ferring, which holds a patent on Carbetocins room temperature-stable (RTS) version, produces it in India for domestic and international markets like Africa.Carbetocin's current form is heat-resistant and therefore does not need to be refrigerated, which is a problem in low- and lower-middle-income countries.

Last year, Ferrings introduced heat-stable Carbetocin in the region, as part of the ProjectFamilySafebirth initiative, and now plans to expand it to other remote villages and areas.The deployment of heat-stable Carbetocin into public hospitals has just begun, and the response has been encouraging, according to Alexandra, Ferring board member & Countess of Frederiksborg of Denmark.Every hour, four women die losing their lives in India, and postpartum hemorrhage is still the most preventable event.To maintain its consistency and efficiency, the first-choice drug, mainly Oxytocin, for preventing excessive bleeding after birth required storage and transportation at 28C, usually in a freezer.In low- and low-income countries, where many of them have a hot climate and unpredictable energy sources, the lack of cold storage is a challenge.

The results led to the inclusion of heat-stable Carbetocin in the WHO Model List of Essential Medicines, according to the Registrar General of India study, the maternal mortality rate in India has decreased by ten points from 2016-18 to 103 in 2017-19.According to WHO recommendations, Ferring is committed to reduce the MMR to less than 70 per 100,000 live births by 2030, according to Falk.Menopur (IVF) & Pentasa (GI) are two of the company's most popular selling brands here, with the organization also providing services in the reproductive sciences, GI, and uro-oncology fields.Along with an R&D center at Hyderabad, it is expanding its formulation unit for GI drugs at Hyderabad.